Literature DB >> 15231198

[Analysis on the cost and its related factors of clinically confirmeds severe acute respiratory syndrome cases in Beijing].

Feng Xiao1, Bo-wen Chen, Yang-feng Wu, Yue-xiang Wang, De-min Han.   

Abstract

OBJECTIVE: To explore the medical cost and its related factors of clinically confirmed severe acute respiratory syndrome (SARS) cases in Beijing.
METHODS: The average medical cost per person/day was calculated on 1272 SARS cases with complete hospitalization data from the Beijing SARS clinical database. Factors associated with medical expenditure were explored by both single factor and multi-factor analyses.
RESULTS: The medical costs of SARS patients in Beijing were 18 767.50 RMB/case and 632.02 RMB/day/case. Expenses on medication accounted for the highest proportion (0.66%). The increase in expenses on medication was significantly associated to the increase in total expenditure. Analyses by single factor, factor stratification as well as multi-factor analyses showed that: the expenditure increased significantly with the following factors of the patients: prolonged days of hospitalization, severe symptoms and signs, hospitalization at the early stage of disease onset, being medical staff themselves, with baseline diseases, being applied mechanical ventilation, and with medical insurance.
CONCLUSIONS: The medical expenditure on SARS patients at the hospital was higher than that on patients with common diseases which was associated to the following factors as: days of hospitalization, severity of disease, stage of the disease break-out, patient's occupation, baseline disease status, medical insurance status etc.

Entities:  

Mesh:

Year:  2004        PMID: 15231198

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  6 in total

1.  Calculating the burden of disease of avian-origin H7N9 infections in China.

Authors:  Xiaopeng Qi; Dong Jiang; Hongliang Wang; Dafang Zhuang; Jiaqi Ma; Jingying Fu; Jingdong Qu; Yan Sun; Shicheng Yu; Yujie Meng; Yaohuan Huang; Lanfang Xia; Yingying Li; Yong Wang; Guohua Wang; Ke Xu; Qun Zhang; Ming Wan; Xuemei Su; Gang Fu; George F Gao
Journal:  BMJ Open       Date:  2014-01-17       Impact factor: 2.692

2.  Economic burden and its associated factors of hospitalized patients infected with A (H7N9) virus: a retrospective study in Eastern China, 2013-2014.

Authors:  Xiang Huo; Li-Ling Chen; Lei Hong; Lun-Hui Xiang; Fen-Yang Tang; Shan-Hui Chen; Qiang Gao; Cong Chen; Qi-Gang Dai; Chuan-Wu Sun; Ke Xu; Wen-Jun Dai; Xian Qi; Chang-Cheng Li; Hui-Yan Yu; Yin Zhou; Hao-Di Huang; Xing-Yang Pan; Chang-Sha Xu; Ming-Hao Zhou; Chang-Jun Bao
Journal:  Infect Dis Poverty       Date:  2016-09-01       Impact factor: 4.520

3.  Economic burden of COVID-19, China, January-March, 2020: a cost-of-illness study.

Authors:  Huajie Jin; Haiyin Wang; Xiao Li; Weiwei Zheng; Shanke Ye; Sheng Zhang; Jiahui Zhou; Mark Pennington
Journal:  Bull World Health Organ       Date:  2020-11-30       Impact factor: 9.408

4.  Diagnostic and Therapeutic Costs of Patients With a Diagnosis of or Suspected Coronavirus Disease in Iran.

Authors:  Hosein Ebrahimipour; Hassan Haghparast-Bidgoli; Shapour Badiee Aval; Seyed Javad Hoseini; Sara Jamili; Zahra Ebnehoseini; Marjan Vejdani; Amin Adel
Journal:  Value Health Reg Issues       Date:  2021-11-13

5.  Nurses' core emergency competencies for COVID-19 in China: A cross-sectional study.

Authors:  Hongdan Li; Shuju Dong; Li He; Rui Wang; Shiyan Long; Fengming He; Huairong Tang; Ling Feng
Journal:  Int Nurs Rev       Date:  2021-05-27       Impact factor: 3.384

6.  Hospitalization costs of coronaviruses diseases in upper-middle-income countries: A systematic review.

Authors:  César Ramos Rocha-Filho; Johnny Wallef Leite Martins; Rosa Camila Lucchetta; Gabriel Sodré Ramalho; Giulia Fernandes Moça Trevisani; Aline Pereira da Rocha; Ana Carolina Pereira Nunes Pinto; Felipe Sebastião de Assis Reis; Laura Jantsch Ferla; Patrícia de Carvalho Mastroianni; Luci Correa; Humberto Saconato; Virgínia Fernandes Moça Trevisani
Journal:  PLoS One       Date:  2022-03-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.